美罗华治疗侵袭性B细胞淋巴瘤的临床观察

Mabthera for Aggressive B-cell Lymphoma:Clinical Observation

目的评价在CHOP方案(环磷酰胺+吡喃阿霉素+长春新碱+强的松)化疗的基础上加用美罗华治疗侵袭性B细胞淋巴瘤患者的疗效。方法 60例侵袭性B细胞淋巴瘤患者,分成观察组和对照组。对照组:CHOP方案化疗;观察组:美罗华+CHOP方案化疗。结果观察组的CR率与CR+PR率均明显高于对照组,差异具有统计学意义(P<0.01或0.05)。两组最主要的不良反应为骨髓抑制和胃肠道反应等,差异均无统计学意义(P>0.05)。两组均无治疗相关的死亡病例。结论在CHOP方案化疗的基础上加用美罗华治疗侵袭性B细胞淋巴瘤患者疗效佳,而且也未增加骨髓毒性、胃肠道反应及肝肾功能损害,值得临床推广应用。

Objective To evaluate the therapy effect of mabthera and CHOP （cyclophosphamide ＋ pirarubicin ＋ vincristine ＋ prednisone） chemotherapy in aggressive B-cell lymphoma. Methods Sixty cases of aggressive B-cell lymphoma were divided into observation group and control group,and the control group was given CHOP induction chemotherapy and the observation group was given mabthera ＋ CHOP induction chemotherapy. Results The CR rate and CR ＋ PR rate of the observation group were higher than those of the control group,with a significant difference （P〈O.01 or O.05,Table 1）. There were no significant differences in the main adverse reactions of bone marrow suppression and gastrointestinal tract between the two groups （P〉0.05,Table 2）. Two groups had no treatment-related deaths. Conclusion Mabthera and CHOP induction chemotherapy in the treatment of aggressive B-cell lymphoma is effective,with no increase in bone marrow toxicity,gastrointestinal reactions and liver and kidney dysfunction,worthy of being clinically promoted.